Johnson & Johnson tells shareholders its pipeline is meant to offset patent-driven pressure
A new shareholder communication highlighted how future drug launches are expected to help counter revenue declines tied to loss of patent protection.
Business headlines from the Apex backend, organized by sectors and major public companies for faster market scanning.
A new shareholder communication highlighted how future drug launches are expected to help counter revenue declines tied to loss of patent protection.
THE APEX TIMES
In a new discussion of “agentic” artificial intelligence, Salesforce executives describe how autonomous systems can complete an intrusion in milliseconds, forcing defenders to add guardrails, human approvals, and governance before AI is allowed to act.
A new market snapshot framed by Yahoo Finance suggests Meta’s AI effort is not being priced with the same momentum as peers, even as mega-cap rivals continue to attract investor attention around artificial intelligence.
A trial update tied to Moderna and Merck’s cancer vaccine effort sparked a sharp market reaction, underscoring investor appetite for new immunotherapy platforms. Still, the post did not provide enough technical detail to gauge durability or scale of benefit.
Tesla’s stock jumped in afternoon trading after new permit filings indicated the company is preparing a dedicated wireless charging hub to support its upcoming Cybercab fleet.
The retailer says it will apply the refunds to items including groceries and general merchandise, aiming to offset costs tied to tariffs.
A new market-data snapshot from Yahoo Finance examines whether Leonardo DRS, Inc. is trading stronger than aerospace and defense peers so far this year, using year-to-date stock performance as the yardstick.
A tariff refund did little to offset a shortfall in comparable sales, with the gap showing up as the retailer reported a softer quarter.
Bristol Myers Squibb and Johnson & Johnson are among the large companies drawing attention to Seaport Therapeutics after the biotech went public, following a strategy pitch built around prodrug development and board-level connections to recent neuroscience deals.